These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 22951438)

  • 1. Fluid biomarkers in Alzheimer disease.
    Blennow K; Zetterberg H; Fagan AM
    Cold Spring Harb Perspect Med; 2012 Sep; 2(9):a006221. PubMed ID: 22951438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
    Blennow K; Hampel H; Weiner M; Zetterberg H
    Nat Rev Neurol; 2010 Mar; 6(3):131-44. PubMed ID: 20157306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular markers of Alzheimer disease early diagnostic: investigation perspectives of peripheral tissues.].
    Paltsev MA; Zuev VA; Kozhevnikova EO; Linkova NS; Kvetnaia TV; Polyakova VO; Kvetnoy IM
    Adv Gerontol; 2017; 30(6):809-817. PubMed ID: 29608821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
    Rosén C; Andreasson U; Mattsson N; Marcusson J; Minthon L; Andreasen N; Blennow K; Zetterberg H
    Neuromolecular Med; 2012 Mar; 14(1):65-73. PubMed ID: 22350541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluid biomarkers in Alzheimer's disease - current concepts.
    Rosén C; Hansson O; Blennow K; Zetterberg H
    Mol Neurodegener; 2013 Jun; 8():20. PubMed ID: 23800368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
    Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM
    Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients.
    Zhang M; Zhong X; Shi H; Vanmechelen E; De Vos A; Liu S; Chen B; Mai N; Peng Q; Chen X; Wu Z; Hou L; Zhou H; Ouyang C; Zhang W; Liang W; Dai C; Ning Y
    J Alzheimers Dis; 2020; 77(1):313-322. PubMed ID: 32804135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.
    Engelborghs S; Le Bastard N
    Mol Diagn Ther; 2012 Jun; 16(3):135-41. PubMed ID: 22646065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study.
    Pais M; Loureiro J; do Vale V; Radanovic M; Talib L; Stella F; Forlenza O
    J Alzheimers Dis; 2021; 81(3):949-962. PubMed ID: 33843685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia.
    Santangelo R; Dell'Edera A; Sala A; Cecchetti G; Masserini F; Caso F; Pinto P; Leocani L; Falautano M; Passerini G; Martinelli V; Comi G; Perani D; Magnani G
    Curr Alzheimer Res; 2019; 16(7):587-595. PubMed ID: 31345148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.